Not our first
vegetarian capsules. 

But certainly our
most targeted.

LEARN MORE

Scroll down

Introducing ACGcapsTM HX our time-dependent delayed release capsule, made without using animal products of any kind in its formulation. 


ACGcapsTM HX allows for the delayed release of capsule contents, shielding them from stomach acid. This capsule is suitable for enzymes, probiotics, and other thermolabile ingredients and, as a bonus, also masks contents odour and aftertaste. 


So what does all this mean? Well, this may not be the first vegetarian capsule we’ve ever made, but it’s certainly one of the best. 

Contact us to learn more about the range.

Go to article: Home | Big Tech meets Big PharmaGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: ProceedixGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: SanofiGo to article: ILC Dover Go to article: NiproGo to article: ACG WorldwideGo to article: CommentGo to article: Covid-19 vaccine effectiveness affected by variantsGo to article: Immuno-oncology high prescriber survey reveals top R&D strategiesGo to article: Using methotrexate may reduce the negative impact of high treatment-related costGo to article: Protecting against fake Covid-19 vaccinesGo to article: Cytiva Company Insight Go to article: CytivaGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: In DepthGo to article: Is big pharma and big tech working together a recipe for success?Go to article: Logging in: how the pharma industry is getting to grips with social media Go to article: Medical cannabis: regulating a new export market on the Isle of ManGo to article: Long Covid: could chronic fatigue syndrome be taken seriously at last?Go to article: Life after Covid-19: four ways to prepare for the next pandemicGo to article: mRNA vaccines: the post-pandemic outlook after a breakthrough yearGo to article: Staving off AMR disaster with Ineos and the University of OxfordGo to article: Public benefit: could the PBC model help pharma balance profits and patients?Go to article: The Solubility Company Insight Go to article: The Solubility companyGo to article: ButterworthGo to article: MicronovaGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue